Skip to main content
OpenTrials
Completed

NCT Number: NCT00905645

Sientra Sponsored Silimed Gel-Filled Breast Implant Core Clinical Study

Safety and effectiveness of the Silimed Gel-Filled Mammary Implant as indicated for primary augmentation, primary reconstruction, and/or revision of the female breast.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Sientra, Inc.

Santa Barbara, California, 93117, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects are admitted into the study only if all of the following eligibility is true:

  • Female
  • Age limitation specific to the indication:
  • Primary Augmentation: Must be 18 years or older
  • Primary Reconstruction: No age limit
  • Revision: If original surgery was primary reconstruction, then no age limit. If original surgery was primary augmentation, then must be 18 years or older.
  • Adequate tissue available to cover implant(s)
  • Willingness to follow study requirements (informed consent form, follow-up visits)
  • Candidate for primary augmentation, primary reconstruction, or revision

Exclusion criteria

Subjects are not eligible if any of the following criteria exist:

  • Advanced fibrocystic disease, considered to be pre-malignant without mastectomy
  • Inadequate or unsuitable tissue
  • Active infection in the body at the time of surgery
  • Pregnant or lactating
  • Medical condition that might result in unduly high surgical risk and/or significant postoperative complications, in the judgment of the Investigator
  • Use of drugs, including any drug that would interfere with blood clotting, that might result in high risk and/or significant postoperative complications
  • Demonstrated psychological characteristics that are unrealistic or unreasonable given the risks involved with the surgical procedure
  • Determination by physical examination that the subject does have any connective tissue/autoimmune disorder
  • Existing carcinoma of the breast without accompanying mastectomy
  • MRI scan is prohibited because of implanted metal device, claustrophobia, or other condition.

Treatment and study plan

Silimed Gel-Filled Mammary Implant

Device

Primary outcomes

  1. Local Complications

    Time frame: 10 Years

    Assessment of the safety of the Study Implants is based on the incidence of adverse events through 10 years.

Secondary outcomes

  1. Satisfaction Determined by Patients

    Time frame: 10 Years

    Assessment of the effectiveness of Study Implants based on patient satisfaction using a 5-point scale where 1=strongly agree to 5= strongly disagree. The patient satisfaction measures through 10 years provided in the table below are based on questionnaire responses of "Strongly Agree" and "Agree."

Sponsors and collaborators

Lead sponsor

Tiger Biosciences, LLC.

Industry

Registry information

Official study title

Sientra Sponsored Silimed Gel-Filled Mammary Implant Clinical Study Protocol: Core Clinical Investigation

Important dates

Study start
2002
Primary completion
2018
Study completion
2018
First posted
May 20, 2009
Registry last updated
Jan 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.